Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04988867 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04988867 is a Phase 2 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT04988867, a Phase 2 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls with Rett syndrome
Interventions
- DRUG Trofinetide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04988867
The ClinicalTrials.gov registry entry for NCT04988867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trofinetide is the first listed.
NCT04988867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04988867 about?
NCT04988867 is a clinical study titled "An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome". To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls with Rett syndrome
What is the current status of trial NCT04988867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-09-22. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04988867?
The interventions under investigation include: Trofinetide (DRUG).
Who is sponsoring clinical trial NCT04988867?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.